【Tanvex-KY】Subsidiary Tanvex BioPharma USA, Inc. Receives Complete Response Letter (CRL) from U.S. FDA Regarding Biosimilar Drug TX05 (Herceptin Biosimilar) Due to Inspection Issues at Downstream Fill-Finish Facility
AI Summary (NQ-processed)
Tanvex BioPharma USA, Inc., a 100%-owned subsidiary of Tanvex-KY, has received a Complete Response Letter (CRL) from the U.S. FDA regarding its biosimilar drug TX05 (Herceptin biosimilar). The CRL stems from inspection issues at a downstream fill-finish manufacturing facility. No concerns were raised about the drug substance manufactured by Tanvex US. A response is expected to be submitted by the end of July 2026.
AI Analysis
Frequently Asked Questions
Q: What is a CRL from the FDA?
A: A Complete Response Letter indicates the FDA has completed its review but requires additional information or corrections before approval.
Q: What conditions does TX05 treat?
A: TX05 is indicated for breast and gastric cancers, same as the reference drug Herceptin.
Q: What is the market size in the U.S.?
A: According to IQVIA, Herceptin and biosimilars generated about $1 billion in U.S. sales over the past year.
Q: What is the next step?
A: Tanvex US will submit a response to the FDA by end of July 2026, addressing the manufacturing site issues.
Q: Is this a major setback for the company?
A: No, the drug substance was not questioned. This is a solvable manufacturing partner issue.